April 24, 2019
EpimAb Biotherapeutics is Granted US Patent on Core Bispecific Antibody Technology
Based on EpimAb’sglobally filed first application, this patent broadly covers bispecificantibodies obtained utilizing the company’s FIT-Ig®technology in a composition of matter claim.